{
    "id": "dbpedia_2417_2",
    "rank": 8,
    "data": {
        "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228689/",
        "read_more_link": "",
        "language": "en",
        "title": "Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation.",
        "top_image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "meta_img": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "images": [
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-pmbook2pmc.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Oliver Rivero-Arias",
            "May Ee Png",
            "Ashley White",
            "Miaoqing Yang",
            "Sian Taylor-Phillips",
            "Lisa Hinton",
            "Felicity Boardman",
            "Abigail McNiven",
            "Jane Fisher",
            "Baskaran Thilaganathan"
        ],
        "publish_date": "2024-06-27T00:00:00",
        "summary": "",
        "meta_description": "Health economic assessments are used to determine whether the resources needed to generate net benefit from an antenatal or newborn screening programme, driven by multiple benefits and harms, are justifiable. It is not known what benefits and harms have ...",
        "meta_lang": "en",
        "meta_favicon": "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico",
        "meta_site_name": "PubMed Central (PMC)",
        "canonical_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228689/",
        "text": "Health Technol Assess. 2024 Jun; 28(25): 1–180.\n\nPMCID: PMC11228689\n\nPMID: 38938110\n\nBenefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation.\n\nAbstract\n\nBACKGROUND\n\nHealth economic assessments are used to determine whether the resources needed to generate net benefit from an antenatal or newborn screening programme, driven by multiple benefits and harms, are justifiable. It is not known what benefits and harms have been adopted by economic evaluations assessing these programmes and whether they omit benefits and harms considered important to relevant stakeholders.\n\nOBJECTIVES\n\n(1) To identify the benefits and harms adopted by health economic assessments in this area, and to assess how they have been measured and valued; (2) to identify attributes or relevance to stakeholders that ought to be considered in future economic assessments; and (3) to make recommendations about the benefits and harms that should be considered by these studies.\n\nDESIGN\n\nMixed methods combining systematic review and qualitative work.\n\nSYSTEMATIC REVIEW METHODS\n\nWe searched the published and grey literature from January 2000 to January 2021 using all major electronic databases. Economic evaluations of an antenatal or newborn screening programme in one or more Organisation for Economic Co-operation and Development countries were considered eligible. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards checklist. We identified benefits and harms using an integrative descriptive analysis and constructed a thematic framework.\n\nQUALITATIVE METHODS\n\nWe conducted a meta-ethnography of the existing literature on newborn screening experiences, a secondary analysis of existing individual interviews related to antenatal or newborn screening or living with screened-for conditions, and a thematic analysis of primary data collected with stakeholders about their experiences with screening.\n\nRESULTS\n\nThe literature searches identified 52,244 articles and reports, and 336 unique studies were included. Thematic framework resulted in seven themes: (1) diagnosis of screened for condition, (2) life-years and health status adjustments, (3) treatment, (4) long-term costs, (5) overdiagnosis, (6) pregnancy loss and (7) spillover effects on family members. Diagnosis of screened-for condition (115, 47.5%), life-years and health status adjustments (90, 37.2%) and treatment (88, 36.4%) accounted for most of the benefits and harms evaluating antenatal screening. The same themes accounted for most of the benefits and harms included in studies assessing newborn screening. Long-term costs, overdiagnosis and spillover effects tended to be ignored. The wide-reaching family implications of screening were considered important to stakeholders. We observed good overlap between the thematic framework and the qualitative evidence.\n\nLIMITATIONS\n\nDual data extraction within the systematic literature review was not feasible due to the large number of studies included. It was difficult to recruit healthcare professionals in the stakeholder's interviews.\n\nCONCLUSIONS\n\nThere is no consistency in the selection of benefits and harms used in health economic assessments in this area, suggesting that additional methods guidance is needed. Our proposed thematic framework can be used to guide the development of future health economic assessments evaluating antenatal and newborn screening programmes.\n\nSTUDY REGISTRATION\n\nThis study is registered as PROSPERO CRD42020165236.\n\nFUNDING\n\nThis award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR127489) and is published in full in Health Technology Assessment; Vol. 28, No. 25. See the NIHR Funding and Awards website for further award information.\n\nPlain language summary\n\nEvery year the NHS offers pregnant women screening tests to assess the chances of them or their unborn baby having or developing a health condition. It also offers screening tests for newborn babies to look for a range of health conditions. The implementation of screening programmes and the care for women and babies require many resources and funding for the NHS, so it is important that screening programmes represent good value for money. This means that the amount of money the NHS spends on a programme is justified by the amount of benefit that the programme gives. We wanted to see whether researchers consider all the important benefits and harms associated with screening of pregnant women and newborn babies when calculating value for money. To do this, we searched all studies available in developed countries to identify what benefits and harms they considered. We also considered the views of parents and healthcare professionals on the benefits and harms screening that creates for families and wider society. We found that the identification of benefits and harms of screening is complex because screening results affect a range of people (mother–baby, parents, extended family and wider society). Researchers calculating the value for money of screening programmes have, to date, concentrated on a narrow range of benefits and harms and ignored many factors that are important to people affected by screening results. From our discussions with parents and healthcare professionals, we found that wider impacts on families are an important consideration. Only one study we looked at considered wider impacts on families. Our work also found that parent’s ability to recognise, absorb and apply new information to understand their child’s screening results or condition is important. Healthcare professionals involve in screening should consider this when supporting families of children with a condition. We have created a list for researchers to identify the benefits and harms that are important to include in future studies. We have also identified different ways researchers can value these benefits and harms, so they are incorporated into their studies in a meaningful way.\n\nFull text of this article can be found in Bookshelf.\n\nReferences\n\nRaffle A, Muir Gray JA. Screening: Evidence and Practice. Oxford: Oxford University Press; 2019.\n\nPetticrew M, Sowden A, Lister-Sharp D, Wright K. False-negative results in screening programmes: systematic review of impact and implications. Health Technol Assess 2000;4(5):1–20. [PubMed]\n\nKuppermann M, Nease JR, Gates E, Learman L, Blumberg B, Gildengorin V, et al. How do women of diverse backgrounds value prenatal testing outcomes? Prenat Diagn 2004;24(6):424–9. [PubMed]\n\nKuppermann M, Norton M, Thao K, O’Leary A, Nseyo O, Cortez A, et al. Preferences regarding contemporary prenatal genetic tests among women desiring testing: implications for optimal testing strategies. Prenat Diagn 2016;36(5):469–75. [PubMed]\n\nKaimal AJ, Norton ME, Kuppermann M. Prenatal testing in the genomic age: clinical outcomes, quality of life, and costs. Obstet Gynecol 2015;126(4):737–46. [PubMed]\n\nWoolf-King S, Anger A, Arnold E, Weiss S, Teitel D. Mental health among parents of children with critical congenital heart defects: a systematic review. J Am Heart Assoc 2017;6(2):e004862. [PMC free article] [PubMed]\n\nFuller A, Horváth-Puhó E, Ray J, Ehrenstein V, Sørensen H, Cohen E. Mortality among parents of children with major congenital anomalies. Pediatrics 2021;147(5):e2020028571. [PubMed]\n\nDavies V, Gledhill J, McFadyen A, Whitlow B, Economides D. Psychological outcome in women undergoing termination of pregnancy for ultrasound-detected fetal anomaly in the first and second trimesters: a pilot study. Ultrasound Obstet Gynecol 2005;25(4):389–92. [PubMed]\n\nKorenromp M, Christiaens G, van den Bout J, Mulder E, Hunfeld J, Bilardo C, et al. Long-term psychological consequences of pregnancy termination for fetal abnormality: a cross-sectional study. Prenat Diagn 2005;25(3):253–60. [PubMed]\n\nFriedman J, Cornel M, Goldenberg A, Lister K, Sénécal K, Vears D. Genomic newborn screening: public health policy considerations and recommendations. BMC Med Genomics 2017;10(1):1–3. [PMC free article] [PubMed]\n\nPhillips K, Deverka P, Marshall D, Wordsworth S, Regier D, Christensen K, et al. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. Value Health 2018;21(9):1033–42. [PMC free article] [PubMed]\n\nPublic Health England. UK NSC: Evidence Review Process. URL: www.gov.uk/government/publications/uk-nsc-evidence-review-process/uk-nsc-evidence-review-process (accessed 11 May 2020).\n\nWaugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess 2013;35:1–90. [PMC free article] [PubMed]\n\nNational Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. URL: www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 3 October 2019). [PubMed]\n\nScottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form. URL: www.scottishmedicines.org.uk/making-a-submission/ (accessed 23 July 2021).\n\nHaute Autorité de Santé. Choices in Methods for Economic Evaluation. URL: http://has-sante.fr/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf (accessed 11 May 2020).\n\nAustralian Government Department of Health. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). URL: https://pbac.pbs.gov.au (accessed 11 May 2020).\n\nCanadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada. URL: www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition (accessed 11 May 2020).\n\nWeinstein M, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice of decision analytic modeling in health care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6(1):9–17. [PubMed]\n\nKarnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, et al. A review and critique of modelling in prioritising and designing screening programmes. Health Technol Assess 2007;11(52):iii–137. [PubMed]\n\nSimon J, Petrou S, Gray A. The valuation of prenatal life in economic evaluations of perinatal interventions. Health Econ 2009;18(4):487–94. [PubMed]\n\nPetrou S. Methodological limitations of economic evaluations of antenatal screening. Health Econ 2001;10(8):775–8. [PubMed]\n\nKwon J, Kim SW, Ungar WJ, Tsiplova K, Madan J, Petrou S. A systematic review and meta-analysis of childhood health utilities. Med Decis Making 2018;38(3):277–305. [PubMed]\n\nAl-Janabi H, van Exel J, Brouwer W, Coast J. A framework for including family health spillovers in economic evaluation. Med Decis Making 2016;36(2):176–86. [PMC free article] [PubMed]\n\nWright SJ, Ulph F, Dharni N, Payne K. Eliciting preferences for information provision in newborn bloodspot screening programs. Value Health 2017;20(4):651–61. [PubMed]\n\nBeulen L, Grutters JPC, Faas BHW, Feenstra I, Groenewoud H, van Vugt JMG, et al. Women’s and healthcare professionals’ preferences for prenatal testing: a discrete choice experiment. Prenat Diagn 2015;35(6):549–57. [PubMed]\n\nNuffield Council on Bioethics. Non-invasive Prenatal Testing: Ethical Issues. URL: www.nuffieldbioethics.org/assets/pdfs/NIPT-ethical-issues-full-report.pdf (accessed 20 July 2020).\n\nHasegawa LE, Fergus KA, Ojeda N, Au SM. Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies. Public Health Genomics 2011;14(4–5):298–306. [PMC free article] [PubMed]\n\nSilcock C, Liao LM, Hill M, Chitty LS. Will the introduction of non-invasive prenatal testing for Down’s syndrome undermine informed choice? Health Expect 2015;18(5):1658–71. [PMC free article] [PubMed]\n\nCacciatore P, Visser LA, Buyukkaramikli N, van der Ploeg CPB, van den Akker-van Marle ME. The methodological quality and challenges in conducting economic evaluations of newborn screening: a scoping review. Int J Neonatal Screen 2020;6(4):94. [PMC free article] [PubMed]\n\nLanger A, Holle R, John J. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. BMC Health Serv Res 2012;12:300. [PMC free article] [PubMed]\n\nMcMillan I. The Listening Series: Including Everyone in Public Engagement with Research. Guidance for Researchers. URL: https://tv.ndph.ox.ac.uk/wp-content/uploads/2022/01/Listening-Series-Guide-for-Researchers.pdf (accessed 22 March 2022).\n\nStaniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ 2017;358:3453. [PMC free article] [PubMed]\n\nHinton L, Miller T. Mapping men’s anticipations and experiences in the reproductive realm: (in)fertility journeys. Reprod Biomed Online 2013;27(3):244–52. [PubMed]\n\nLocock L, Kai J. Parents’ experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract 2008;58(548):161–8. [PMC free article] [PubMed]\n\nBoardman FK. The expressivist objection to prenatal testing: the experiences of families living with genetic disease. Soc Sci Med 2014;107:18–25. [PubMed]\n\nPublic Health England. Antenatal Screening Standards: Data Report 1 April 2018 to 31 March 2019. URL: www.gov.uk/government/statistics/antenatal-screening-standards-data-report-2018-to-2019/antenatal-screening-standards-data-report-1-april-2018-to-31-march-2019--2 (accessed 28 March 2022).\n\nPng ME, Yang M, Roberts N, Taylor-Phillips S, Rivero-Arias O, Petrou S. Methods for evaluating the benefits and harms of antenatal and newborn screening programmes adopted by health economic assessments: protocol for a systematic review. BMJ Open 2021;11(8):e048031. [PMC free article] [PubMed]\n\nPage M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. [PMC free article] [PubMed]\n\nOrganisation for Economic Co-operation and Development (OECD). List of OECD Member Countries – Ratification of the Convention on the OECD. URL: www.oecd.org/about/document/list-oecd-member-countries.htm (accessed 12 November 2020).\n\nTaylor-Phillips S, Stinton C, di Ruffano LF, Seedat F, Clarke A, Deeks JJ. Association between use of systematic reviews and national policy recommendations on screening newborn babies for rare diseases: systematic review and meta-analysis. BMJ 2018;361:k1612. [PMC free article] [PubMed]\n\nCanadian Agency for Drugs and Technologies in Health (CADTH) (2011). Grey Matters: A Practical Search Tool for Evidence-based Medicine. URL: https://cadth.ca/resources/finding-evidence/grey-matters (accessed 20 December 2022).\n\nHiggins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. URL: www.training.cochrane.org/handbook (accessed 22nd August 2023).\n\nVeritas Health Innovation. Covidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation; 2024. URL: www.covidence.org (accessed March 2024).\n\nHusereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049. [PubMed]\n\nHusereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ 2022;376:e067975. [PMC free article] [PubMed]\n\nMorse J. Confusing categories and themes. Qual Health Res 2008;18(6):727–8. [PubMed]\n\nSandelowski M. What’s in a name? Qualitative description revisited. Res Nurs Health 2010;33(1):77–84. [PubMed]\n\nWhite A, Boardman F, McNiven A, Locock L, Hinton L. Absorbing it all: a meta-ethnography of parents’ unfolding experiences of newborn screening. Soc Sci Med 2021;287:114367. [PMC free article] [PubMed]\n\nBearman M, Dawson P. Qualitative synthesis and systematic review in health professions education. Med Educ 2013;47(3):252–60. [PubMed]\n\nAlt S, McHugh A, Permalloo N, Pandya P. Fetal anomaly screening programme. Obstet Gynaecol Reprod Med 2020;30(12):395–7.\n\nWhite AL, Boardman F, McNiven A, Locock L, Hinton L. Absorbing it all: a meta-ethnography of parents’ unfolding experiences of newborn screening. Soc Sci Med 2021;287:114367. [PMC free article] [PubMed]\n\nYu J. A systematic review of issues around antenatal screening and prenatal diagnostic testing for genetic disorders: women of Asian origin in western countries. Health Soc Care Community 2012;20(4):329–46. [PubMed]\n\nLafarge C, Mitchell K, Fox P. Termination of pregnancy for fetal abnormality: a meta-ethnography of women’s experiences. Reprod Health Matters 2014;22(44):191–201. https://doi.org/101016/S0968-8080(14)44799-2 [PubMed]\n\nDheensa S, Metcalfe A, Williams RA. Men’s experiences of antenatal screening: a metasynthesis of the qualitative research. Int J Nurs Stud 2013;50(1):121–33. [PubMed]\n\nReid B, Sinclair M, Barr O, Dobbs F, Crealey G. A meta-synthesis of pregnant women’s decision-making processes with regard to antenatal screening for Down syndrome. Soc Sci Med 2009;69(11):1561–73. [PubMed]\n\nMoncrieff G, Finlayson K, Cordey S, McCrimmon R, Harris C, Barreix M, et al. First and second trimester ultrasound in pregnancy: a systematic review and metasynthesis of the views and experiences of pregnant women, partners, and health workers. PLOS ONE 2021;16(12):e0261096. [PMC free article] [PubMed]\n\nJohnson J, Dunning A, Sattar R, Arezina J, Karkowsky EC, Thomas S, Panagioti M. Delivering unexpected news via obstetric ultrasound: a systematic review and meta-ethnographic synthesis of expectant parent and staff experiences. Sonography 2020;7(2):61–77.\n\nGenomics England. Genomics England. URL: www.genomicsengland.co.uk/ (accessed 12 September 2022).\n\nFinfgeld D. Metasynthesis: the state of the art – so far. Qual Health Res 2003;13(7):893–904. [PubMed]\n\nErwin E, Brotherson M, Summers J. Understanding qualitative metasynthesis: issues and opportunities in early childhood intervention research. J Early Interv 2011;33(3):186–200.\n\nBarnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol 2009;9(1):59. [PMC free article] [PubMed]\n\nToye F, Seers K, Allcock N, Briggs M, Carr E, Barker K. Meta-ethnography 25 years on: challenges and insights for synthesising a large number of qualitative studies. BMC Med Res Methodol 2014;14(1):1–4. [PMC free article] [PubMed]\n\nLudvigsen M, Hall E, Meyer G, Fegran L, Aagaard H, Uhrenfeldt L. Using Sandelowski and Barroso’s meta-synthesis method in advancing qualitative evidence. Qual Health Res 2016;26(3):320–9. [PubMed]\n\nPublic Health England. Newborn Blood Spot Screening: Programme Handbook. URL: www.gov.uk/government/publications/hea lth-professional-handbook-newborn-blood-spot-screening (accessed 7 September 2021).\n\nNicholls S. Proceduralisation, choice and parental reflections on decisions to accept newborn bloodspot screening. J Med Ethics 2012;38(5):299–303. [PubMed]\n\nNicholls S. Knowledge or understanding? Informed choice in the context of newborn bloodspot screening. Public Health Ethics 2010;3(2):128–36.\n\nNicholls S, Southern K. Parental decision-making and acceptance of newborn bloodspot screening: an exploratory study. PLOS ONE 2013;8(11):e79441. [PMC free article] [PubMed]\n\nParsons E, King J, Israel J, Bradley D. Mothers’ accounts of screening newborn babies in Wales (UK). Midwifery 2007;23(1):59–65. [PubMed]\n\nChudleigh J, Buckingham S, Dignan J, O’Driscoll S, Johnson K, Rees D, et al. Parents’ experiences of receiving the initial positive newborn screening (NBS) result for cystic fibrosis and sickle cell disease. J Genet Couns 2016;25(6):1215–26. [PMC free article] [PubMed]\n\nBuchbinder M, Timmermans S. Newborn screening and maternal diagnosis: rethinking family benefit. Soc Sci Med 2011;73(7):1014–8. [PubMed]\n\nBuchbinder M, Timmermans S. Newborn screening for metabolic disorders: parental perceptions of the initial communication of results. Clin Pediatr (Phila) 2012;51(8):739–44. [PubMed]\n\nGrob R. Parenting in the genomic age: the ‘cursed blessing’ of newborn screening. New Genet Soc 2006;25(2):159–70.\n\nTimmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav 2010;51(4):408–23. [PubMed]\n\nUlph F, Cullinan T, Qureshi N, Kai J. Parents’ responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening. Eur J Human Genet 2015;23(4):459–65. [PMC free article] [PubMed]\n\nTluczek A. Psychosocial issues associated with genetic testing in cystic fibrosis newborn screening. Nurs Health Sci 2006;8(2):127.\n\nGrob R. Is my sick child healthy? Is my healthy child sick?: changing parental experiences of cystic fibrosis in the age of expanded newborn screening. Soc Sci Med 2008;67(7):1056–64. [PubMed]\n\nCohen W, Quarterly DL. Absorptive capacity: a new perspective on learning and innovation. Adm Sci Q 1990;35(1):128–52.\n\nMoran J, Quirk K, Duff A, Fibrosis KB. Newborn screening for CF in a regional paediatric centre: the psychosocial effects of false-positive IRT results on parents. J Cyst Fibrosis 2007;6(3):250–4. [PubMed]\n\nSalm N, Yetter E, Tluczek A. Informing parents about positive newborn screen results: parents’ recommendations. J Child Health Care 2012;16(4):367–81. [PMC free article] [PubMed]\n\nSchwan K, Youngblom J, Weisiger K, Kianmahd J, Waggoner R, Fanos J. Family perspectives on newborn screening for X-linked adrenoleukodystrophy in California. Int J Neonatal Screen 2019;5(4):42. [PMC free article] [PubMed]\n\nTluczek A, McKechnie AC, Lynam PA. When the cystic fibrosis label does not fit: a modified uncertainty theory. Qual Health Res 2010;20(2):209–23. [PMC free article] [PubMed]\n\nBoyse K, Gardner M, Marvicsin DJ, Sandberg DE. ‘It was an overwhelming thing’: parents’ needs after infant diagnosis with congenital adrenal hyperplasia. J Pediatr Nurs 2014;29(5):436–41. [PMC free article] [PubMed]\n\nLocock L, Kai J. Parents’ experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract 2008;58(548):161–8. [PMC free article] [PubMed]\n\nTluczek A, Orland K, Nick SW, Brown RL. Newborn screening: an appeal for improved parent education. J Perinat Neonatal Nurs 2009;23(4):326. [PMC free article] [PubMed]\n\nCarpenter K, Wittkowski A, Hare DJ, Medford E, Rust S, Jones SA, Smith DM. Parenting a Child with Phenylketonuria (PKU): an Interpretative Phenomenological Analysis (IPA) of the experience of parents. J Genet Couns 2018;27(5):1074–86. [PMC free article] [PubMed]\n\nPatterson RP, Roedl SJ, Farrell MH. Internet searching after parents receive abnormal newborn screening results. J Commun Healthc 2015;8(4):303–15.\n\nRaz A, Amano Y, Timmermans S. Parents like me: biosociality and lay expertise in self-help groups of parents of screen-positive newborns. New Genet Soc 2018;37(2):97–116.\n\nPruniski B, Lisi E, Ali N. Newborn screening for Pompe disease: impact on families. J Inherit Metab Dis 2018;41(6):1189–203. [PubMed]\n\nJohnson F, Southern K, Ulph F. Psychological impact on parents of an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis: a qualitative study. Int J Neonatal Screen 2019;5(2):23. [PMC free article] [PubMed]\n\nHart J, Cox C, Kuhn I, Fritz Z. Communicating diagnostic uncertainty in the acute and emergency medical setting: a systematic review and ethical analysis of the empirical literature. Acute Med 2021;20(3):204–18. [PubMed]\n\nDeLuca J, Kearney M, Norton S, Arnold GL. Parents’ experiences of expanded newborn screening evaluations. Pediatrics 2011;128(1):53–61. [PubMed]\n\nTluczek A, Koscik RL, Modaff P, Pfeil D, Rock MJ, Farrell PM, et al. Newborn screening for cystic fibrosis: parents’ preferences regarding counseling at the time of infants’ sweat test. J Genet Couns 2006;15(4):277–91. [PubMed]\n\nTluczek A, Orland KM, Cavanagh L. Psychosocial consequences of false-positive newborn screens for cystic fibrosis. Qual Health Res 2011;21(2):174–86. [PMC free article] [PubMed]\n\nBuchbinder M, Timmermans S. Medical technologies and the dream of the perfect newborn. Med Anthropol 2011;30(1):56–80. [PubMed]\n\nRaz AE, Amano Y, Timmermans S. Coming to terms with the imperfectly normal child: attitudes of Israeli parents of screen-positive infants regarding subsequent prenatal diagnosis. J Community Genet 2019;10(1):41–50. [PMC free article] [PubMed]\n\nUlph F, Cullinan T, Qureshi N. Informing children of their newborn screening carrier result for sickle cell or cystic fibrosis: qualitative study of parents’ intentions, views and support needs. J Genet Couns 2014;23(3):409–20. [PubMed]\n\nGrob R. Qualitative research on expanded prenatal and newborn screening: robust but marginalized. Hastings Cent Rep 2019;49(S1):S72–81. [PMC free article] [PubMed]\n\nClarke AE. Situational analyses: grounded theory mapping after the postmodern turn. Symb Interact 2003;26(4):553–76.\n\nGrzanka PR. The shape of knowledge: situational analysis in counseling psychology research. J Couns Psychol 2021;68(3):316–30. [PubMed]\n\nSaldana J. The Coding Manual for Qualitative Researchers. 3rd edn. London: SAGE Publications; 2016.\n\nPope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. BMJ 2000;320(7227):114–6. [PMC free article] [PubMed]\n\nZiebland S, McPherson A. Making sense of qualitative data analysis: an introduction with illustrations from DIPEx (personal experiences of health and illness). Med Educ 2006;40(5):405–14. [PubMed]\n\nRyan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001;5(5). [PubMed]\n\nRyan M, Kinghorn P, Entwistle VA, Francis JJ. Valuing patients’ experiences of healthcare processes: towards broader applications of existing methods. Soc Sci Med 2014;106:194–203. [PMC free article] [PubMed]\n\nParkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost–utility analysis? Health Econ 2006;15(7):653–64. [PubMed]\n\nVass CM, Georgsson S, Ulph F, Payne K. Preferences for aspects of antenatal and newborn screening: a systematic review. BMC Pregnancy Childbirth 2019;19(1):1–11. [PMC free article] [PubMed]\n\nKwon J, Freijser L, Huynh E, Howell M, Chen G, Khan K, et al. Systematic review of conceptual, age, measurement and valuation considerations for generic multidimensional childhood patient-reported outcome measures. Pharmacoeconomics 2022;40:379–431. [PMC free article] [PubMed]\n\nJabrayilov R, van Asselt ADI, Vermeulen KM, Volger S, Detzel P, Dainelli L, et al. A descriptive system for the Infant health-related Quality of life Instrument (IQI): measuring health with a mobile app. PLOS ONE 2018;13(8):e0203276. [PMC free article] [PubMed]\n\nVerstraete J, Ramma L, Jelsma J. Item generation for a proxy health related quality of life measure in very young children. Health Qual Life Outcomes 2020;18(1):1–15. [PMC free article] [PubMed]\n\nDonaldson C, Shackley P, Abdalla M, Miedzybrodzka Z. Willingness to pay for antenatal carrier screening for cystic fibrosis. Health Econ 1995;4(6):439–52. [PubMed]\n\nLin PJ, Yeh WS, Neumann PJ. Willingness to pay for a newborn screening test for spinal muscular atrophy. Pediatr Neurol 2017;66:69–75. [PubMed]\n\nRouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000;183(2):400–6. [PubMed]\n\nVintzileos AM, Ananth CV, Smulian JC, Beazoglou T, Knuppel RA. Routine second-trimester ultrasonography in the United States: a cost–benefit analysis. Am J Obstet Gynecol 2000;182(3):655–60. [PubMed]\n\nWald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). Health Technol Assess 2003;7(11):1–77. [PubMed]\n\nWalker B, Jackson B, LaGrave D, Ashwood E, Schmidt R. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenat Diagn 2015;35(5):440–6. [PubMed]\n\nBerrigan P, Andrew G, Reynolds JN, Zwicker JD. The cost-effectiveness of screening tools used in the diagnosis of fetal alcohol spectrum disorder: a modelled analysis. BMC Public Health 2019;19(1):1746. [PMC free article] [PubMed]\n\nAbbey R, Dunsmoor-Su R. Cost–benefit analysis of indirect antiglobulin screening in Rh(D)-negative women at 28 weeks of gestation. Obstet Gynecol 2014;123(5):938–45. [PubMed]\n\nAlbright CM, Emerson JB, Werner EF, Hughes BL. Third-trimester prenatal syphilis screening: a cost-effectiveness analysis. Obstet Gynecol 2015;126(3):479–85. [PubMed]\n\nZaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. JAIDS J Acquir Immune Defic Syndr 2000;25(5):403–16. [PubMed]\n\nDaniels J, Gray J, Pattison H, Roberts T, Edwards E, Milner P, et al. Rapid testing for group B streptococcus during labour: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technol Assess 2009;13(42):1–154, iii. [PubMed]\n\nDoyle NM, Levison JE, Gardner MO. Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis. Am J Obstet Gynecol 2005;193(3 Pt 2):1280–5. [PubMed]\n\nDuplantie J, Gonzales OM, Bois A, Nshimyumukiza L, Gekas J, Bujold E, et al. Cost-effectiveness of the management of Rh-negative pregnant women. J Obstet Gynaecol Canada 2013;35(8):730–40. [PubMed]\n\nGomez M. A comparison of three screening strategies for prevention of perinatal HIV infection in Colombia: a decision analysis model. Pan Am J Public Health 2008;24(4):256–64. [PubMed]\n\nImmergluck LC, Cull WL, Schwartz A, Elstein AS. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 2000;105(4):E54. [PubMed]\n\nMol BWJ, van der Veen F, Bossuyt PMM. Symptom-free women at increased risk of ectopic pregnancy: should we screen? Acta Obstet Gynecol Scand 2002;81(7):661–72. [PubMed]\n\nOrtved D, Hawkins TL, Johnson JA, Hyett J, Metcalfe A. Cost-effectiveness of first-trimester screening with early preventative use of aspirin in women at high risk of early-onset pre-eclampsia. Ultrasound Obstet Gynecol 2019;53(2):239–44. [PubMed]\n\nPinot De Moira A, Edmunds WJ, Breuer J. The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles. Vaccine 2006;24(9):1298–307. [PubMed]\n\nPoncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Cost-effectiveness analysis of gestational diabetes mellitus screening in France. Eur J Obstet Gynecol Reprod Biol 2002;103(2):122–9. [PubMed]\n\nRivera-Alsina ME, Rivera CC, Rollene N, Kirby RS, Ayres A, McNamara M. Voluntary screening program for HIV in pregnancy. Cost effectiveness. J Reprod Med 2001;46(3):243–48. [PubMed]\n\nStan CM, Boulvain M, Bovier PA, Auckenthaler R, Berner M, Irion O. Choosing a strategy to prevent neonatal early-onset group B streptococcal sepsis: economic evaluation. BJOG 2001;108(8):840–7. [PubMed]\n\nWastlund D, Moraitis AA, Dacey A, Sovio U, Wilson ECF, Smith GCS. Screening for breech presentation using universal late-pregnancy ultrasonography: a prospective cohort study and cost effectiveness analysis. PLOS Med 2019;16(4):e1002778. [PMC free article] [PubMed]\n\nWilliams M, Zantow E, Turrentine M. Cost effectiveness of latest recommendations for group B streptococci screening in the United States. Obstet Gynecol 2020;10:10. [PubMed]\n\nSansom, S. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol 2003;102(4):782–90. [PubMed]\n\nMrus JM, Tsevat J. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care. Med Decis Making 2004;24(1):30–9. [PubMed]\n\nPark F, Deeming S, Bennett N, Hyett J. Cost effectiveness analysis of a model of first trimester prediction and prevention for preterm preeclampsia against usual care. Ultrasound Obstet Gynecol 2020;58:688–697. [PubMed]\n\nRodriguez PJ, Roberts DA, Meisner J, Sharma M, Owiredu MN, Gomez B, et al. Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study. Lancet Glob Health 2021;9(1):e61–71. [PMC free article] [PubMed]\n\nArentz-Hansen H, Brurberg K, Kvamme M, Stoinska-Schneider A, Hofmann B, Ormstad S, et al. Rhesus typing av foster basert på blodprøve fra rhesus negative gravide. URL: www.fhi.no/globalassets/dokumenterfiler/rapporter/2014/rapport_2014_25_rhesustyping_foster.pdf (accessed 4 March 2024).\n\nHuntington S, Weston G, Adams E. Repeat Screening for Syphilis in Pregnancy as an Alternative Screening Strategy in the UK: A Cost-effectiveness Analysis. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1306%0A (accessed 20 February 2021). [PMC free article] [PubMed]\n\nCastilla-Rodriguez I, Cela E, Vallejo-Torres L, Valcarcel-Nazco C, Dulin E, Espada M, et al. Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain. Expert Opin Orphan Drugs 2016;4(6):567–75.\n\nvan den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006;118(3):896–905. [PubMed]\n\nBenn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M. An economic analysis of cell-free DNA non-invasive prenatal testing in the US general pregnancy population. PLOS ONE 2015;10(7):e0132313. [PMC free article] [PubMed]\n\nBeulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol 2014;182:53–61. [PubMed]\n\nBiggio JR Jr, Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004;190(3):721–9. [PubMed]\n\nBramley D, Graves N, Walker D. The cost effectiveness of universal antenatal screening for HIV in New Zealand. AIDS 2003;17(5):741–8. [PubMed]\n\nChristiansen M, Olesen Larsen S. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 2002;22(6):482–6. [PubMed]\n\nChung EH, Lim SL, Havrilesky LJ, Steiner AZ, Dotters-Katz S. The cost-effectiveness of prenatal congenital heart defect screening methods in IVF pregnancies. Ultrasound Obstet Gynecol 2020;18:18. [PubMed]\n\nDhaifalah I, Majek O. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic. Ceska Gynekol 2012;77(1):39–51. [PubMed]\n\nDormandy E, Bryan S, Gulliford M, Roberts T, Ades A, Calnan M, et al. Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial. Health Technol Assess 2010;14(20):1–60. [PubMed]\n\nGekas J, Durand A, Bujold E, Vallee M, Forest JC, Rousseau F, Reinharz D. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used? Am J Obstet Gynecol 2011;204(2):175.e1–8. [PubMed]\n\nGekas J, Gagne G, Bujold E, Douillard D, Forest JC, Reinharz D, Rousseau F. Comparison of different strategies in prenatal screening for Down’s syndrome: cost effectiveness analysis of computer simulation. BMJ 2009;338:b138. [PMC free article] [PubMed]\n\nGilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M, van Der Meulen JH. Screening for Down’s syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323(7310):423–5. [PMC free article] [PubMed]\n\nGraves N, Walker DG, McDonald AM, Kaldor JM, Ziegler JB. Would universal antenatal screening for HIV infection be cost-effective in a setting of very low prevalence? Modelling the data for Australia. J Infect Dis 2004;190(1):166–74. [PubMed]\n\nHacker F, Griffin E, Shaffer B, Caughey A. Role of sequential genetic sonogram and cellfree fetal DNA after EIF detection: a cost-effectiveness analysis. Am J Obstet Gynecol 2017;216 (1 Suppl.):S95–6.\n\nHacker F, Griffin E, Shaffer B, Caughey A. Role of genetic sonogram and NIPT after EIF detection: a cost-effectiveness analysis. Am J Obstet Gynecol 2015;212(1):S171–2.\n\nHacker FM, Griffin EE, Shaffer BL, Caughey AB. Role of genetic ultrasonogram after choroid plexus cyst detection a cost-effectiveness analysis. Obstet Gynecol 2015;125:116S.\n\nHarris AH. The cost effectiveness of prenatal ultrasound screening for trisomy 21. Int J Technol Assess Health Care 2004;20(4):464–8. [PubMed]\n\nHealth Quality Ontario. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions: a Health Technology Assessment. Ont Health Technol Assess Ser 2019;19(4):1–166. [PMC free article] [PubMed]\n\nNorman R, van Gool K, Hall J, Delatycki M, Massie J. Cost-effectiveness of carrier screening for cystic fibrosis in Australia. J Cyst Fibrosis 2012;11(4):281–7. [PubMed]\n\nOdibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol 2005;106(3):562–8. [PubMed]\n\nResch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr 2005;38(2):163–73. [PubMed]\n\nRitchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. BJOG 2005;112(7):866–74. [PubMed]\n\nUdeh B, Udeh C, Graves N. Perinatal HIV transmission and the cost-effectiveness of screening at 14 weeks gestation, at the onset of labour and the rapid testing of infants. BMC Infect Dis 2008;8:174. [PMC free article] [PubMed]\n\nVanara F, Bergeretti F, Gaglioti P, Todros T. Economic evaluation of ultrasound screening options for structural fetal malformations. Ultrasound Obstet Gynecol 2004;24(6):633–9. [PubMed]\n\nVintzileos AM, Ananth CV, Smulian JC, Day-Salvatore DL, Beazoglou T, Knuppel RA. Cost–benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol 2000;95(4):577–83. [PubMed]\n\nXie X, Wang M, Goh ES, Ungar WJ, Little J, Carroll JC, et al. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions in average-risk pregnancies: a cost-effectiveness analysis. J Obstet Gynaecol Canada 2020;31:31. [PubMed]\n\nNielsen R, Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002;11(4):285–99. [PubMed]\n\nKessels S, Morona J, Mittal R, Vogan A, Newton S, Schubert C, et al. Testing for Hereditary Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. www1.health.gov.au/internet/msac/publishing.nsf/Content/D54C11627FEA9785CA25801000123BDC/$File/1216-MSAC-CA-CFTR.pdf%0A (accessed 20 February 2021).\n\nAyres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol 2014;54(5):412–7. [PubMed]\n\nBayon JC, Orruno E, Portillo MI, Asua J. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis. Cost Eff Resour Alloc 2019;17:6. [PMC free article] [PubMed]\n\nBricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, et al. Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women’s views. Health Technol Assess 2000;4(16):i–vi, 1. [PubMed]\n\nCaughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002;187(5):1239–45. [PubMed]\n\nDeVore GR, Romero R. Genetic sonography: a cost-effective method for evaluating women 35 years and older who decline genetic amniocentesis. J Ultrasound Med 2002;21(1):5–13. [PubMed]\n\nDi Cianni G, Volpe L, Casadidio I, Bottone P, Marselli L, Lencioni C, et al. Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy. Acta Diabetol 2002;39(2):69–73. [PubMed]\n\nFairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. J Matern-Fetal Neonatal Med 2016;29(7):1160–4. [PMC free article] [PubMed]\n\nGekas J, van den Berg DG, Durand A, Vallee M, Wildschut HI, Bujold E, et al. Rapid testing versus karyotyping in Down’s syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities. Eur J Hum Genet 2011;19(1):3–9. [PMC free article] [PubMed]\n\nJuvet LK, Ormstad SS, Stoinska-Schneider A, Solberg B, Arentz-Hansen H, Kvamme MK, et al. Non-invasive prenatal test (NIPT) for identification of trisomy 21, 18 and 13. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016. NIPH Systematic Reviews: Executive Summaries. [PubMed]\n\nNshimyumukiza L, Beaumont JA, Duplantie J, Langlois S, Little J, Audibert F, et al. Cell-free DNA-based non-invasive prenatal screening for common aneuploidies in a Canadian province: a cost-effectiveness analysis. J Obstet Gynaecol Canada 2018;40(1):48–60. [PubMed]\n\nOhno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool – a cost-effectiveness analysis. Prenat Diagn 2013;33(7):630–5. [PubMed]\n\nO’Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013;53(5):425–33. [PubMed]\n\nOng JJ, Chen M, Hocking J, Fairley CK, Carter R, Bulfone L, Hsueh A. Chlamydia screening for pregnant women aged 16–25 years attending an antenatal service: a cost-effectiveness study. BJOG 2016;123(7):1194–202. [PubMed]\n\nPinto NM, Nelson R, Puchalski M, Metz TD, Smith KJ. Cost-effectiveness of prenatal screening strategies for congenital heart disease. Ultrasound Obstet Gynecol 2014;44(1):50–7. [PMC free article] [PubMed]\n\nSong K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern-Fetal Neonatal Med 2013;26(12):1180–5. [PMC free article] [PubMed]\n\nWalker B, Nelson R, Jackson B, Grenache D, Ashwood E, Schmidt R. A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States. PLOS ONE 2015;10(7):e0131402. [PMC free article] [PubMed]\n\nTaylor-Phillips S, Freeman K, Geppert J, Madan J, Uthman O, Agbebiyi A, et al. Systematic Review and Cost-consequence Assessment of Cell-free DNA Testing for T21, T18 and T13 in the UK: Final Report. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1265%0A (accessed 20 February 2021).\n\nHoogendoorn M, Hamberg-van Reenen H, van Genugten M, de Wit G, Schielen P. Vergelijking van kosten en effecten van prenatale screeningsmethoden voor Down syndroom en neuraalbuisdefecten. URL: https://www.rivm.nl/bibliotheek/rapporten/230041001.pdf%0A (accessed 20 February 2021).\n\nInstitute of Health Economics. First and Second Trimester Prenatal Screening Update. URL: http://www.inahta.org/upload/2014/14043_IHE_First and second trimester prenatal screening update.pdf (accessed 17 February 2021).\n\nHulstaert F, Neyt M, Gyselaers W. The Non-invasive Prenatal Test (NIPT) for Trisomy 21: Health Economic Aspects. URL: https://kce.fgov.be/sites/default/files/atoms/files/KCE_222_Non_invasive_prenatal_ test_Report.pdf (accessed 20 February 2021).\n\nNational Institute for Health and Care Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. NG3, Feb 2015 (Appendix N.3). URL: www.nice.org.uk/guidance/ng3/evidence/appendices-ag-and-in-pdf-3784286%0A (accessed 20 February 2021). [PubMed]\n\nBoshuizen HC, van der Lem GJ, Kauffman-de Boer MA, van Zanten GA, Oudesluys-Murphy AM, Verkerk PH. Costs of different strategies for neonatal hearing screening: a modelling approach. Arch Dis Child Fetal Neonatal Ed 2001;85(3):F177–81. [PMC free article] [PubMed]\n\nBurke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. Int J Pediatr Otorhinolaryngol 2012;76(2):212–8. [PubMed]\n\nChicaiza-Becerra L, Garcia-Molina M, Oviedo-Ariza S, Gomez-Marin JE, Gomez-Sanchez PI. Cost effectiveness of various diagnostic strategies for detecting congenital toxoplasmosis in newborns. Infectio 2013;17(2):53–60.\n\nHessel F, Grill E, Schnell-Inderst P, Siebert U, Kunze S, Nickisch A, et al. Economic evaluation of newborn hearing screening: modelling costs and outcomes. Ger Med Sci 2003;1:Doc09. [PMC free article] [PubMed]\n\nInstitute of Health Economics. Newborn Blood Spot Screening for Galactosemia, Tyrosinemia Type I, Homocystinuria, Sickle Cell Anemia, Sickle Cell/Beta-thalassemia, Sickle Cell/Hemoglobin C Disease, and Severe Combined Immunodeficiency. Vol. 3. p. 3. Edmonton, AB: Institute of Health Economics; 2016. [PubMed]\n\nKemper AR, Downs SM. A cost-effectiveness analysis of newborn hearing screening strategies. Arch Pediatr Adolesc Med 2000;154(5):484–8. [PubMed]\n\nLondono Trujillo D, Sandoval Reyes NF, Taborda Restrepo A, Chamorro Velasquez CL, Dominguez Torres MT, Romero Ducuara SV, et al. Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia. Cost Eff Resour Alloc 2019;17:11. [PMC free article] [PubMed]\n\nNshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge AM, Fournier D, et al. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study. J Cyst Fibrosis 2014;13(3):267–74. [PubMed]\n\nRaimond V, Sambuc C, Pibouleau L. Ethics evaluation revealing decision-maker motives: a case of neonatal screening. Int J Technol Assess Health Care 2018;34(2):189–95. [PubMed]\n\nRamwadhdoebe S, Van Merode GG, Boere-Boonekamp MM, Sakkers RJ, Buskens E. Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the Netherlands. BMC Health Serv Res 2010;10:75. [PMC free article] [PubMed]\n\nSchmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L, et al. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium. Acta Clin Belg 2019;75(3):1–9. [PubMed]\n\nSeror V, Cao C, Roussey M, Giorgi R. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study. J Med Screen 2016;23(2):62–9. [PubMed]\n\nZupancic JAF, Ying GS, Alba Campomanes A de, Tomlinson LA, Binenbaum G; G-ROP Study Group. Evaluation of the economic impact of modified screening criteria for retinopathy of prematurity from the Postnatal Growth and ROP (G-ROP) study. J Perinatol 2020;40(7):1100–8. [PMC free article] [PubMed]\n\nTran K, Banerjee S, Li H, Noorani H, Mensinkai S, Dooley K. Newborn Screening for Medium Chain Acyl-CoA Dehydrogenase Deficiency Using Tandem Mass Spectrometry: Clinical and Cost-effectiveness. URL: https://pubmed.ncbi.nlm.nih.gov/17222812/ (accessed 4 March 2024). [PubMed]\n\nInstitute of Health Economics. Screening Newborns for Hearing. URL: www.ihe.ca/download/screening_newborns_for_hearing.pdf%0A (accessed 20 February 2021).\n\nHillman SC, Barton PM, Roberts TE, Maher ER, McMullan DM, Kilby MD. BAC chromosomal microarray for prenatal detection of chromosome anomalies in fetal ultrasound anomalies: an economic evaluation. Fetal Diagn Ther 2014;36(1):49–58. [PubMed]\n\nKott B, Dubinsky TJ. Cost-effectiveness model for first-trimester versus second-trimester ultrasound screening for Down syndrome. J Am Coll Radiol 2004;1(6):415–21. [PubMed]\n\nLe Bras A, Salomon LJ, Bussieres L, Malan V, Elie C, Mahallati H, et al. Cost-effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model-based analysis. Ultrasound in Obstet Gynecol 2019;54(5):596–603. [PubMed]\n\nFeuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 2006;117(5 Pt 2):S280–6. [PubMed]\n\nGriebsch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparing the clinical and economic effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for congenital heart defects: a probabilistic cost-effectiveness model and value of information analysis. Int J Technol Assess Health Care 2007;23(2):192–204. [PubMed]\n\nKeren R, Helfand M, Homer C, McPhillips H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002;110(5):855–64. [PubMed]\n\nKezirian EJ, White KR, Yueh B, Sullivan SD. Cost and cost-effectiveness of universal screening for hearing loss in newborns. Otolaryngol Head Neck Surg 2001;124(4):359–67. [PubMed]\n\nKnowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. Health Technol Assess 2005;9(44):1–152, iii. [PubMed]\n\nLanting CI, van Tijn DA, Loeber JG, Vulsma T, de Vijlder JJ, Verkerk PH. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. Pediatrics 2005;116(1):168–73. [PubMed]\n\nNarayen IC, Te Pas AB, Blom NA, van den Akker-van Marle ME. Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge. Eur J Pediatr 2019;178(1):97–103. [PMC free article] [PubMed]\n\nRoberts T, Pickering K, Barton P, Ewer A. Pulse Oximetry as a Screening Test for Critical Congenital Heart Defects and Other Significant Diagnoses in Newborn Infants: A Cost Effectiveness Analysis. URL: https://legacyscreening.phe.org.uk/documents/pulse-oximetry/PO Health Economics Report.pdf%0A (accessed 20 February 2021).\n\nHubbard HB. Expanded newborn screening for genetic and metabolic disorders: modeling costs and outcomes. Nurs Econ 2007;25(6):345–52. [PubMed]\n\nHopkins MK, Dugoff L, Durnwald C, Havrilesky LJ, Dotters-Katz S. Cell-free DNA for Down syndrome screening in obese women: is it a cost-effective strategy? Prenat Diagn 2020;40(2):173–8. [PubMed]\n\nSinkey RG, Odibo AO. Vasa previa screening strategies: decision and cost-effectiveness analysis. Ultrasound Obstet Gynecol 2018;52(4):522–29. [PubMed]\n\nMukerji A, Shafey A, Jain A, Cohen E, Shah PS, Sander B, et al. Pulse oximetry screening for critical congenital heart defects in Ontario, Canada: a cost-effectiveness analysis. Can J Public Health 2020;06:6. [PMC free article] [PubMed]\n\nDe Laet C, Hanquet G, Hendrickx E. Multi Criteria Decision Analysis to Select Priority Diseases for Newborn Blood Screening. URL: https://kce.fgov.be/sites/default/files/atoms/files/KCE_267_Newborn_blood_screening.pdf%0A (accessed 20 February 2021).\n\nCipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 2007;10(2):83–97. [PubMed]\n\nBergevin A, Zick CD, McVicar SB, Park AH. Cost–benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection. Int J Pediatr Otorhinolaryngol 2015;79(12):2090–3. [PubMed]\n\nBonds DE, Freedberg KA. Cost-effectiveness of prenatal screening for postpartum thyroiditis. J Womens Health Gend Based Med 2001;10(7):649–58. [PubMed]\n\nDosiou C, Barnes J, Schwartz A, Negro R, Crapo L, Stagnaro-Green A. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J Clin Endocrinol Metab 2012;97(5):1536–46. [PubMed]\n\nDosiou C, Sanders GD, Araki SS, Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol 2008;158(6):841–51. [PubMed]\n\nTasillo A, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, et al. Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care. Obstet Gynecol 2019;133(2):289–300. [PMC free article] [PubMed]\n\nBessey A, Chilcott JB, Leaviss J, Sutton A. Economic impact of screening for X-linked adrenoleukodystrophy within a newborn blood spot screening programme. Orphanet J Rare Dis 2018;13(1):179. [PMC free article] [PubMed]\n\nPeterson C, Grosse SD, Oster ME, Olney RS, Cassell CH. Cost-effectiveness of routine screening for critical congenital heart disease in US newborns. Pediatrics 2013;132(3):e595–603. [PMC free article] [PubMed]\n\nTiwana SK, Rascati KL, Park H. Cost-effectiveness of expanded newborn screening in Texas. Value Health 2012;15(5):613–21. [PubMed]\n\nCahill AG, Odibo AO, Stamilio DM, Macones GA. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis. Am J Obstet Gynecol 2009;201(5):466.e1–7. [PubMed]\n\nOhno M, Cheng YW, Shaffer B, Caughey AB. A new test to diagnose Down syndrome using maternal serum: at what specificity, sensitivity, and cost is it cost-effective? Am J Obstet Gynecol 2011;204 (1 Suppl.):S236–7.\n\nChowers M, Shavit O. Economic evaluation of universal prenatal HIV screening compared with current ‘at risk’ policy in a very low prevalence country. Sex Transm Infect 2017;93(2):112–7. [PubMed]\n\nCipriano LE, Barth WH Jr, Zaric GS. The cost-effectiveness of targeted or universal screening for vasa praevia at 18–20 weeks of gestation in Ontario. BJOG 2010;117(9):1108–8. [PubMed]\n\nDarlington M, Carbonne B, Mailloux A, Brossard Y, Levy-Mozziconacci A, Cortey A, et al. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. BMC Pregnancy Childbirth 2018;18(1):496. [PMC free article] [PubMed]\n\nFarrar D, Simmonds M, Griffin S, Duarte A, Lawlor DA, Sculpher M, et al. The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technol Assess 2016;20(86):1–348. [PMC free article] [PubMed]\n\nGantt S, Dionne F, Kozak FK, Goshen O, Goldfarb DM, Park AH, et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr 2016;170(12):1173–80. [PubMed]\n\nHauspurg A, Albright C, Rouse D, Werner E. Third trimester fetal growth ultrasound: a cost–benefit analysis. Am J Obstet Gynecol 2015;212(1):S285.\n\nHersh AR, Megli CJ, Caughey AB. Repeat screening for syphilis in the third trimester of pregnancy: a cost-effectiveness analysis. Obstet Gynecol 2018;132(3):699–707. [PubMed]\n\nImaz-Iglesia I, Miguel LGS, Ayala-Morillas LE, Garcia-Perez L, Gonzalez-Enriquez J, Blasco-Hernandez T, et al. Economic evaluation of chagas disease screening in Spain. Acta Trop 2015;148:77–88. [PubMed]\n\nKowada A. Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries. J Infect 2014;68(1):32–42. [PubMed]\n\nLittle SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 2010;202(3):253.e1–7. [PubMed]\n\nMarseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern-Fetal Neonatal Med 2013;26(8):802–10. [PubMed]\n\nMistry H, Gardiner HM. The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening. J Telemed Telecare 2013;19(4):190–6. [PubMed]\n\nPlunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005;192(4):1153–61. [PubMed]\n\nRound JA, Jacklin P, Fraser RB, Hughes RG, Mugglestone MA, Holt RI. Screening for gestational diabetes mellitus: cost–utility of different screening strategies based on a woman’s individual risk of disease. Diabetologia 2011;54(2):256–63. [PubMed]\n\nRozenbaum MH, Verweel G, Folkerts DK, Dronkers F, van den Hoek JA, Hartwig NG, et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. Int J STD AIDS 2008;19(10):668–75. [PubMed]\n\nSelvapatt N, Ward T, Bailey H, Bennett H, Thorne C, See LM, et al. Is antenatal screening for hepatitis C virus cost-effective? A decade’s experience at a London centre. J Hepatol 2015;63(4):797–804. [PubMed]\n\nShmueli A, Meiri H, Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn 2012;32(1):29–38. [PubMed]\n\nTurner ML, Bessos H, Fagge T, Harkness M, Rentoul F, Seymour J, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion (Paris) 2005;45(12):1945–56. [PubMed]\n\nWetzel S, Miller ES, Cirino N, Dukhovny D, Ameel B, Caughey AB. Routine antenatal screening for depression: what are the outcomes and is it cost-effective? Am J Obstet Gynecol 2016;214(1):S383–4.\n\nWu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10(11):1–110. [PubMed]\n\nZhang W, Mohammadi T, Sou J, Anis AH. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: a microsimulation modeling analysis. PLOS ONE 2019;14(12):e0225281. [PMC free article] [PubMed]\n\nEijsink JFH, Al Khayat M, Boersma C, Horst PGJ ter, Wilschut JC, Postma MJ. Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. Eur J Health Econ 2021;22(1):75–88. [PMC free article] [PubMed]\n\nNational Collaborating Centre for Women’s and Children’s Health. Antenatal Care Routine Care for the Healthy Pregnant Woman (Appendix G). URL: https://stratog.rcog.org.uk/sites/default/files/Induction of labour and prolonged pregnancy/nice_antenatalcare_62_2008_pg15.pdf%0A (accessed 20 February 2021).\n\nCarroll AE, Downs SM. Comprehensive cost–utility analysis of newborn screening strategies. Pediatrics 2006;117(5 Pt 2):S287–95. [PubMed]\n\nCastillo-Riquelme MC, Lord J, Moseley MJ, Fielder AR, Haines L. Cost-effectiveness of digital photographic screening for retinopathy of prematurity in the United Kingdom. Int J Technol Assess Health Care 2004;20(2):201–13. [PubMed]\n\nChan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab 2011;104(3):383–9. [PMC free article] [PubMed]\n\nDing Y, Thompson JD, Kobrynski L, Ojodu J, Zarbalian G, Grosse SD. Cost-effectiveness/cost–benefit analysis of newborn screening for severe combined immune deficiency in Washington state. J Pediatr 2016;172:127–35. [PMC free article] [PubMed]\n\nFox DA, Ronsley R, Khowaja AR, Haim A, Vallance H, Sinclair G, et al. Clinical impact and cost efficacy of newborn screening for congenital adrenal hyperplasia. J Pediatr 2020;7:7. [PubMed]\n\nHamers FF, Rumeau-Pichon C. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France. BMC Pediatr 2012;12:60. [PMC free article] [PubMed]\n\nHerrero C, Moreno-Ternero JD. Hospital costs and social costs: a case study of newborn hearing screening. Invest Econ 2005;29(1):203–16.\n\nInsinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002;141(4):524–31. [PubMed]\n\nMasucci L, Schreiber RA, Kaczorowski J, Collet JP, Bryan S. Universal screening of newborns for biliary atresia: cost-effectiveness of alternative strategies. J Med Screen 2019;26(3):113–9. [PubMed]\n\nMcGhee SA, Stiehm ER, McCabe ER. Potential costs and benefits of newborn screening for severe combined immunodeficiency. J Pediatr 2005;147(5):603–8. [PubMed]\n\nPandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8(12):iii, 1–121. [PubMed]\n\nPanepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000;136(2):201–8. [PubMed]\n\nPfeil J, Listl S, Hoffmann GF, Kolker S, Lindner M, Burgard P. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Orphanet J Rare Dis 2013;8:167. [PMC free article] [PubMed]\n\nProsser LA, Kong CY, Rusinak D, Waisbren SL. Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 2010;125(2):e286–94. [PubMed]\n\nSchoen EJ, Baker JC, Colby CJ, To TT. Cost–benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110(4):781–6. [PubMed]\n\nSchreiber RA, Masucci L, Kaczorowski J, Collet JP, Lutley P, Espinosa V, Bryan S. Home-based screening for biliary atresia using infant stool colour cards: a large-scale prospective cohort study and cost-effectiveness analysis. J Med Screen 2014;21(3):126–32. [PubMed]\n\nSimpson N, Anderson R, Sassi F, Pitman A, Lewis P, Tu K, et al. The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc 2005;3:8. [PMC free article] [PubMed]\n\nVallejo-Torres L, Castilla I, Couce ML, Perez-Cerda C, Martin-Hernandez E, Pineda M, et al. Cost-effectiveness analysis of a national newborn screening programme for biotinidase deficiency. Pediatrics 2015;136(2):e424–32. [PubMed]\n\nvan der Hilst CS, Derks TG, Reijngoud DJ, Smit GP, TenVergert EM. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of the Netherlands. J Pediatr 2007;151(2):115–20, 120.e1. [PubMed]\n\nvan der Ploeg CPB, Blom M, Bredius RGM, van der Burg M, Schielen P, Verkerk PH, et al. Cost-effectiveness of newborn screening for severe combined immunodeficiency. Eur J Pediatr 2019;178(5):721–9. [PubMed]\n\nvan der Ploeg CP, van den Akker-van Marle ME, Vernooij-van Langen AM, Elvers LH, Gille JJ, Verkerk PH, et al. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data. J Cyst Fibrosis 2015;14(2):194–02. [PubMed]\n\nVenditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003;112(5):1005–5. [PubMed]\n\nYoo B, Grosse S. The cost effectiveness of screening newborns for congenital adrenal hyperplasia. Public Health Genomics 2009;12(2):67–72. [PMC free article] [PubMed]\n\nZupancic JA, Triedman JK, Alexander M, Walsh EP, Richardson DK, Berul CI. Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome. J Pediatr 2000;136(4):481–9. [PubMed]\n\nBessey A, Chilcott J, Pandor A, Paisley S. The cost-effectiveness of expanding the UK newborn bloodspot screening programme to include five additional inborn errors of metabolism. Int J Neonatal Screen 2020;6(4):93. [PMC free article] [PubMed]\n\nRichardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, et al. Health and economic outcomes of newborn screening for infantile-onset Pompe disease. Genet Med 2020;23:758–766. [PMC free article] [PubMed]\n\nMogul D, Zhou M, Intihar P, Schwarz K, Frick K. Cost-effective analysis of screening for biliary atresia with the stool color card. J Pediatr Gastroenterol Nutr 2015;60(1):91–98. [PubMed]\n\nBessey A, Chilcott J, Leaviss J, de la Cruz C, Wong R. A cost-effectiveness analysis of newborn screening for severe combined immunodeficiency in the UK. Int J Neonatal Screen 2019;5(3):28. [PMC free article] [PubMed]\n\nHealth Partners Consulting Group. Cost-effectiveness of Newborn Screening for Severe Combined Immune Deficiency. URL: www.nsu.govt.nz/system/files/resources/cost-effectiveness-newborn-screening-severe-combined-immune-deficiency.pdf (accessed 20 February 2021).\n\nTurcotte C, Blancquaert I, Brabant J, St-Louis M. Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem de l’homocystinurie classique (HCY). URL: www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_HCY.pdf%0A (accessed 20 February 2021).\n\nBall RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al. First and Second Trimester Evaluation of Risk (FASTER) research consortium. First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 2007;110(1):10–7. [PubMed]\n\nHan C, Werner E, Pettker C, Norwitz E, Funai E, Thung S. Universal antenatal screening for spinal muscular atrophy (SMA): a cost–utility analysis. Am J Obstet Gynecol 2009;201(6):S261.\n\nHollingsworth B, Harris A. Economic evaluation of prenatal population screening for fragile X syndrome. Community Genet 2005;8(2):68–72. [PubMed]\n\nMusci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005;192(6):1905–12; discussion 1912. [PubMed]\n\nWald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006;26(9):769–77. [PubMed]\n\nPfeil J, Listl S, Hoffmann GF, Kolker S, Lindner M, Burgard P. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Mol Genet Metab 2014;111 (3):299. [PMC free article] [PubMed]\n\nBoyd KA, Briggs AH, Fenwick E, Norrie J, Stock S. Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemp Clin Trials 2011;32(6):893–901. [PubMed]\n\nCahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA, Romero R. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010;202(6):548.e1–8. [PMC free article] [PubMed]\n\nBerger LM. Estimating the benefits and costs of a universal substance abuse screening and treatment referral policy for pregnant women. J Soc Serv Res 2002;29(1):57–84.\n\nKillie MK. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007;114(11):588. [PubMed]\n\nBak GS, Shaffer BL, Madriago E, Allen A, Kelly B, Caughey AB, et al. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective? Ultrasound Obstet Gynecol 2020;56:705–16. [PubMed]\n\nBaker D, Brown Z, Hollier LM, Wendel GD, Hulme L, Griffiths DA, Mauskopf J. Cost-effectiveness of herpes simplex virus type 2 serologic testing and antiviral therapy in pregnancy. Am J Obstet Gynecol 2004;191(6):2074–84. [PubMed]\n\nColbourn T, Asseburg C, Bojke L, Philips Z, Claxton K, Ades A, et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technol Assess 2007;11(29):1–226. [PubMed]\n\nDanyliv A, Gillespie P, O’Neill C, Tierney M, O’Dea A, McGuire BE, et al. The cost-effectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland. Diabetologia 2016;59(3):436–44. [PubMed]\n\nMiller ES, Grobman WA. Cost-effectiveness of transabdominal ultrasound for cervical length screening for preterm birth prevention. Am J Obstet Gynecol 2013;209(6):546.e1–6. [PubMed]\n\nMission JF, Ohno MS, Cheng YW, Caughey AB. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol 2012;207(4):326.e1–9. [PMC free article] [PubMed]\n\nMone F, O’Mahony JF, Tyrrell E, Mulcahy C, McParland P, Breathnach F, et al. Preeclampsia prevention using routine versus screening test-indicated aspirin in low-risk women. Hypertension 2018;72(6):1391–6. [PubMed]\n\nNicholson WK, Fleisher LA, Fox HE, Powe NR. Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies. Diabetes Care 2005;28(6):1482–4. [PubMed]\n\nStraub HL, Antoniewicz LW, Riggs JW, Plunkett BA, Hollier LM. Cost-effectiveness analysis of rubella screening strategies using electronic medical records. Am J Perinatol 2013;30(9):759–64. [PubMed]\n\nThung SF, Grobman WA. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies. Am J Obstet Gynecol 2005;192(2):483–8. [PubMed]\n\nTuite AR, McCabe CJ, Ku J, Fisman DN. Projected cost-savings with herpes simplex virus screening in pregnancy: towards a new screening paradigm. Sex Transm Infect 2011;87(2):141–8. [PubMed]\n\nWastlund D, Moraitis AA, Thornton JG, Sanders J, White IR, Brocklehurst P, et al. The cost-effectiveness of universal late-pregnancy screening for macrosomia in nulliparous women: a decision analysis. BJOG 2019;126(10):1243–50. [PMC free article] [PubMed]\n\nWerner EF, Pettker CM, Zuckerwise L, Reel M, Funai EF, Henderson J, Thung SF. Screening for gestational diabetes mellitus: are the criteria proposed by the international association of the Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care 2012;35(3):529–35. [PMC free article] [PubMed]\n\nOntario H. Noninvasive fetal RhD blood group genotyping: a Health Technology Assessment. Ont Health Technol Assess Ser 2020;20(15):1–160. [PMC free article] [PubMed]\n\nAlbright CM, MacGregor C, Sutton D, Theva M, Hughes BL, Werner EF. Group B streptococci screening before repeat cesarean delivery: a cost-effectiveness analysis. Obstet Gynecol 2017;129(1):111–9. [PubMed]\n\nDunbar JA, Hsu V, Christensen M, Black B, Williams P, Beauchamp G. Cost–utility analysis of screening and laser treatment of retinopathy of prematurity. J Am Assoc Pediatr Ophthalmol Strabismus 2009;13(2):186–90. [PubMed]\n\nHopkins RB, Paradis J, Roshankar T, Bowen J, Tarride JE, Blackhouse G, et al. Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis. J Stud Alcohol Drugs 2008;69(4):510–9. [PubMed]\n\nMalec LM, Sidonio RF Jr, Smith KJ, Cooper JD. Three cost–utility analyses of screening for intracranial hemorrhage in neonates with hemophilia. J Pediatr Hematol Oncol 2014;36(6):474–9. [PubMed]\n\nSocialstyrelsen. Screening för X-bunden adrenoleukodystrofi (X-ALD). URL: www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-screeningprogram/2020-12-7078-halsoekonomisk-analys.pdf%0A (accessed 20 February 2021).\n\nPostma MJ, van den Hoek JA, Beck EJ, Heeg B, Jager JC, Coutinho RA. Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam. Ned Tijdschr Geneeskd 2000;144(16):749–54. [PubMed]\n\nUrbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLOS ONE 2013;8(8):e70319. [PMC free article] [PubMed]\n\nModell V, Knaus M, Modell F. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Immunol Res 2014;60(1):145–52. [PubMed]\n\nQuaglini S, Rognoni C, Spazzolini C, Priori SG, Mannarino S, Schwartz PJ. Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J 2006;27(15):1824–32. [PubMed]\n\nShermock KM, Gildea TR, Singer M, Stoller JK. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis. COPD J Chron Obstruct Pulmon Dis 2005;2(4):411–8. [PubMed]\n\nYeh J, Stout NK, Chaudhry A, Gooch M, McMahon P, Christensen KD, et al. Population-based cancer predisposition testing as a component of newborn screening: a cost effectiveness analysis. J Clin Oncol 2019;37(Suppl. 15):10021.\n\nKanga I, Williams D, Hatchette T, MacKinnon S, Jung H, Black C, et al. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae during pregnancy: Health Technology Assessment. Can Agency Drugs Technol Health 2018. (CADTH health technology assessment report; no. 148). [PubMed]\n\nBak GS, Shaffer BL, Madriago E, Allen A, Kelly B, Caughey AB, et al. Detection of fetal cardiac anomalies: is increasing the number of cardiac views cost-effective? Ultrasound Obstet Gynecol 2020;16:16. [PubMed]\n\nDonnay Candil S, Balsa Barro JA, Alvarez Hernandez J, Crespo Palomo C, Perez-Alcantara F, Polanco Sanchez C. Cost-effectiveness analysis of universal screening for thyroid disease in pregnant women in Spain. Endocrinol Nutr 2015;62(7):322–30. [PubMed]\n\nDorius A, Worstell T, Griffin E, Little S, Sparks T, Caughey A. Routine antenatal testing for pregnancies at 40 weeks gestation: a cost-effectiveness analysis. Am J Obstet Gynecol 2014;210(1):S214–5.\n\nGinsberg GM, Eidelman AI, Shinwell E, Anis E, Peyser R, Lotan Y. Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost–utility analysis. Isr J Health Policy Res 2013;2(1):6. [PMC free article] [PubMed]\n\nLee BY, Wiringa AE, Mitgang EA, McGlone SM, Afriyie AN, Song Y, et al. Routine pre-cesarean Staphylococcus aureus screening and decolonization: a cost-effectiveness analysis. Am J Manag Care 2011;17(10):693–700. [PMC free article] [PubMed]\n\nOdibo AO, Coassolo KM, Stamilio DM, Ural SH, Macones GA. Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies. Prenat Diagn 2006;26(1):39–44. [PubMed]\n\nRours GI, Smith-Norowitz TA, Ditkowsky J, Hammerschlag MR, Verkooyen RP, de Groot R, et al. Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathog Glob Health 2016;110(7–8):292–302. [PMC free article] [PubMed]\n\nScott RK, Crochet S, Huang CC. Universal rapid human immunodeficiency virus screening at delivery: a cost-effectiveness analysis. Infect Dis Obstet Gynecol 2018;2018:6024698. [PMC free article] [PubMed]\n\nSicuri E, Munoz J, Pinazo MJ, Posada E, Sanchez J, Alonso PL, Gascon J. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop 2011;118(2):110–7. [PubMed]\n\nTurrentine MA, Ramirez MM, Mastrobattista JM. Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization. Infect Dis Obstet Gynecol 2009;2009:934698. [PMC free article] [PubMed]\n\nWalker A, Caughey A. Positivity thresholds of HbA1c assay as a screening test for diabetes mellitus in the first trimester in high-risk populations. J Matern-Fetal Neonatal Med 2020;1–5. [PubMed]\n\nHacker FM, Hersh AR, Shaffer BL, Caughey AB. Isolated echogenic intracardiac foci and the role of cell-free fetal DNA: a cost-effectiveness analysis. Prenat Diagn 2020;40(12):1517–24. [PubMed]\n\nAlbright CM, Werner EF, Hughes BL. Cytomegalovirus screening in pregnancy: a cost-effectiveness and threshold analysis. Am J Perinatol 2019;36(7):678–87. [PubMed]\n\nNeovius M, Tiblad E, Westgren M, Kublickas M, Neovius K, Wikman A. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. BJOG 2016;123(8):1337–46. [PubMed]\n\nDitkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost–benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infect Dis 2017;17(1):155. [PMC free article] [PubMed]\n\nDoyle NM, Gardner MO. Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis. Am J Obstet Gynecol 2003;189(3):769–774. [PubMed]\n\nEl Helali N, Giovangrandi Y, Guyot K, Chevet K, Gutmann L, Durand-Zaleski I. Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries. Obstet Gynecol 2012;119(4):822–9. [PubMed]\n\nKekki M, Kurki T, Kotomaki T, Sintonen H, Paavonen J. Cost-effectiveness of screening and treatment for bacterial vaginosis in early pregnancy among women at low risk for preterm birth. Acta Obstet Gynecol Scand 2004;83(1):27–36. [PubMed]\n\nPostma MJ, Bakker A, Welte R, Van Bergen JEAM, Van den Hoek JAR, De Jong-Van den Berg LTW, et al. Screening for asymptomatic infection with Chlamydia trachomatis in pregnancy; favourable cost-effectiveness if prevalence is 3% or more. Ned Tijdschr Geneeskd 2000;144(49):2350–4. [PubMed]\n\nBinquet C, Lejeune C, Seror V, Peyron F, Bertaux AC, Scemama O, et al. The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis. PLOS ONE 2019;14(9):e0221709. [PMC free article] [PubMed]\n\nHaberland CA, Benitz WE, Sanders GD, Pietzsch JB, Yamada S, Nguyen L, Garber AM. Perinatal screening for group B streptococci: cost–benefit analysis of rapid polymerase chain reaction. Pediatrics 2002;110(3):471–80. [PubMed]\n\nPicchiassi E, Coata G, Babucci G, Giardina I, Summa V, Tarquini F, et al. Intrapartum test for detection of group B streptococcus colonization during labor. J Matern-Fetal Neonatal Med 2018;31(24):3293–300. [PubMed]\n\nGeelhoed EA, Lewis B, Hounsome D, O’Leary P. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. J Paediatr Child Health 2005;41(11):575–9. [PubMed]\n\nMagnusson G, Persson U. Screening for congenital cataracts: a cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics. Acta Paediatr 2005;94(8):1089–95. [PubMed]\n\nStillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis 2011;5(9):e1333. [PMC free article] [PubMed]\n\nBrown J, Dezateux C, Karnon J, Parnaby A, Arthur R. Efficiency of alternative policy options for screening for developmental dysplasia of the hip in the United Kingdom. Arch Dis Child 2003;88(9):760–6. [PMC free article] [PubMed]\n\nBrancazio L, Paglia M, Kuller J, Wells S. Prenatal Down syndrome screening: a cost analysis of different strategies. Am J Obstet Gynecol 2003;189(6):S115.\n\nDillard JP, Shen L, Robinson JD, Farrell PM. Parental information seeking following a positive newborn screening for cystic fibrosis. J Health Commun 2010;15(8):880–94. [PMC free article] [PubMed]\n\nKerruish NJ. Parents’ experiences of newborn screening for genetic susceptibility to type 1 diabetes. J Med Ethics 2011;37(6):348–53. [PubMed]\n\nKerruish N. Parents’ experiences 12 years after newborn screening for genetic susceptibility to type 1 diabetes and their attitudes to whole-genome sequencing in newborns. Genet Med 2016;18(3):249–58. [PubMed]\n\nPriddis L, Dougall A, Balding E, Barrett A. Cystic fibrosis diagnosis: impact on mothers of affected Australian children. Neonatal Paediatr Child Health Nurs 2009;12:20–5.\n\nPriddis L, Dunwoodie J, Balding E, Barrett A, Douglas T. Paternal experiences of their children’s diagnosis of Cystic Fibrosis following newborn screening diagnosis. Neonatal Paediatr Child Health Nurs 2010;13(2):3–9.\n\nSchmidt JL, Castellanos-Brown K, Childress S, Bonhomme N, Oktay JS, Terry SF, et al. The impact of false-positive newborn screening results on families: a qualitative study. Genet Med 2012;14(1):76–80. [PubMed]"
    }
}